Acute inflammatory demyelinating polyneuropathy (AIDP) is a sub type of Guillain–Barré syndrome that occurs after the viral and bacterial infections. In the literature a few data are represented on AIDP cases related with Coronavirus-2 (Sars-Cov-2) infections. In this study; a male patient, aged 35 without a known disease is represented. Two weeks before the initial occurrence of typical clinical and electrophysiological AIDP symptoms, the real-time polymerase chain reaction (PCR) test of oropharyngeal swab samples has resulted Covid-19 positive on the patient. The weakness and loss of sensation are observed starting from the lower extremities and continuing along the upper extremities after the remission of respiratory and fever symptoms of the patient in question. Therefore, the patient is diagnosed with segmental demyelinating polyneuropathy by electrophysiological evaluation on the first day of the hospitalisation, following that albuminocytological dissociation is observed by the cerebrospinal fluid (CSF) examination. The remission of symptoms is reported within five-days of intravenous immunoglobin (IVIG) treatment. This study makes difference in the literature by pointing a young patient without underlying chronic medical conditions.Acute inflammatory demyelinating polyneuropathy (AIDP) is a sub type of Guillain–Barré syndrome that occurs after the viral and bacterial infections. In the literature a few data are represented on AIDP cases related with Coronavirus-2 (Sars-Cov-2) infections. In this study; a male patient, aged 35 without a known disease is represented. Two weeks before the initial occurrence of typical clinical and electrophysiological AIDP symptoms, the real-time polymerase chain reaction (PCR) test of oropharyngeal swab samples has resulted Covid-19 positive on the patient. The weakness and loss of sensation are observed starting from the lower extremities and continuing along the upper extremities after the remission of respiratory and fever symptoms of the patient in question. Therefore, the patient is diagnosed with segmental demyelinating polyneuropathy by electrophysiological evaluation on the first day of the hospitalisation, following that albuminocytological dissociation is observed by the cerebrospinal fluid (CSF) examination. The remission of symptoms is reported within five-days of intravenous immunoglobin (IVIG) treatment. This study makes difference in the literature by pointing a young patient without underlying chronic medical conditions.GBS is one of the rare neurological complications of Covid-19; which is an acute-onset, post-infectious, immune-mediated flaccid paralysis with symmetrical involvement from distal to proximal. It is known that Camphylobacter jejuni, EBV, influenza virus and cytomegalovirus are responsible for two-thirds of GBS cases.Alternatively, T cell activation and the release of inflammatory mediators by macrophages can facilitate nerve and myelin damage. It has been concluded that the pathophysiological mechanism of GBS in COVID-19 may be para-infectious. The presented case is clinically and electrophysiologically compatible with AIDP; the age of the patient is younger contrary to the cases reported in the literature which are age of 50 and above. The case presented in this study is one of the youngest patient case reported in the literature.Additionally, while most of the cases in the literature has an underlying chronic disease, in this paper the patient was completely healthy before case.

In conclusion, the possibility of having Covid-19 should be considered in patients with GBS without any respiratory symptoms and Covid-19 may trigger GBS.The Covid19-GBS relationship may be seen in the patients at earlier ages and may have affect people without underlying chronic diseases.Positive response was observed by IVIG treatment in our patient as in many cases in the literature.

Warm Regards,
Alisha
Journal Coordinator
Journal of Translational Neurosciences